Paper Details

  1. Home
  2. Paper Details

LITFULO<sup>TM</sup> (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata.

Author: AbramovitsWilliam, GuptaAditya K, RaviShruthi Polla, VincentKimberly

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

LITFULO<sup>TM</sup> (ritlecitinib) capsules are a newly approved treatment for severe alopecia areata in adolescents and adults. Ritlecitinib is a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family, preventing immune attack on hair follicles. Clinical trials showed that ritlecitinib was effective in reducing hair loss, with a recommended dosage of 50 mg once daily. Common side effects were mild to moderate and included headache, nasopharyngitis, and upper respiratory tract infection.
Paper Details　
Original Abstract of the Article :
LITFULO<sup>TM</sup> (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged &#8805;12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/38051245

データ提供：米国国立医学図書館（NLM）

LITFULOTM (Ritlecitinib): A New Hope for Alopecia Areata

This research highlights the recent approval of LITFULOTM (ritlecitinib) capsules, a novel treatment for severe alopecia areata in adolescents and adults. The researchers investigated the efficacy and safety of ritlecitinib, a Janus kinase 3 (JAK3) inhibitor, in a [research methodology]. The results indicate that ritlecitinib effectively treats severe alopecia areata, offering a potential solution for individuals struggling with this debilitating condition.

A Breakthrough in Alopecia Areata Treatment

The approval of ritlecitinib capsules marks a significant advancement in the treatment of alopecia areata. Its efficacy in reducing hair loss and promoting hair regrowth provides hope for individuals seeking effective treatment options for this condition.

Managing Alopecia Areata: A Holistic Approach

While ritlecitinib offers a promising new treatment option, managing alopecia areata may require a holistic approach. In addition to medication, seeking support from healthcare professionals, incorporating stress-reduction techniques, and exploring alternative therapies can contribute to managing the emotional and psychological aspects of this condition.

Dr.Camel's Conclusion

The desert of hair loss can be a lonely and isolating place. This research, like a refreshing oasis in the middle of a dry expanse, offers a glimmer of hope for individuals struggling with alopecia areata. The development of ritlecitinib capsules provides a potential solution for reducing hair loss and reclaiming a sense of confidence.

Date :
  1. Date Completed 2023-12-07
  2. Date Revised 2023-12-07
Further Info :

Pubmed ID

38051245

DOI: Digital Object Identifier

Related Literature

Article Analysis
・Effects of ritlecitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.